Filing Flows › Cerenome (CNSY) › Q4 2025
Cerenome (CNSY) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 12, 2026
Cerenome (CNSY) reported revenue of $1.4M for the fourth quarter 2025 (Q4 2025), -3% from a year earlier and -2% from the quarter before. Operating margin was -420.0%, net loss $5.7M (417.9% of revenue).
Cerenome, Q4 2025: revenue $1.4M (-3% year over year), operating margin -420.0%, net loss $5.7M, operating cash flow −$6.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | -2% | -3% |
| Operating profit | −$5.7M | — | — |
| Net earnings | −$5.7M | — | — |
| Operating cash flow | −$6.3M | — | — |
What changed
Revenue was $1.4M in Q4 2025, down 3% year over year and down 2% from the previous quarter.
Operating costs exceeded revenue by $5.7M, an operating margin of -420.0%. Total costs grew 34% against a revenue fall of 3%. The fastest-growing cost line was Research & development (+35%). The quarter ended with a net loss of $5.7M, wider than the previous quarter's $4.4M loss.
Operating cash flow was −$6.3M. Non-cash charges added back $145K of depreciation and amortization and $713K of share-based compensation. Working capital and other items used $1.4M. Capital expenditures of $30K exceeded it, leaving free cash flow of −$6.3M.
Questions
What was Cerenome's revenue in the fourth quarter 2025?
Cerenome (CNSY) reported revenue of $1.4M for the fourth quarter 2025 (Q4 2025), -3% from a year earlier and -2% from the quarter before.
Was Cerenome profitable in the fourth quarter 2025?
Operating loss was $5.7M (-420.0% of revenue) and net loss $5.7M.
Source: Cerenome 10-K on SEC EDGAR.